The Genomic Atlas of Breast Cancer — the non-coding theme

Update News

  • GABC update 2020.06.15
  • GABC update 2019.03.20
  • GABC online 2018.08.09
  • Data collection 2018.04.09

About Us

  • Steven Xi Chen:
    steven.chen@miami.edu
  • Yunpeng Zhang:
    YXZ1418@med.miami.edu
  • Peng Wang:
    wpgqy@163.com
  • Shangwei Ning:
    ningsw@ems.hrbmu.edu.cn
  • Xia Li:
    lixia@hrbmu.edu.cn

Detail


Chr chr11
start 1995176
end 2001470
lncRNA name H19
entrez id 283120
hgnc id HGNC:4713
ensg id ENSG00000130600
refseq id NR_002196
methods qPCR, Western blot, RIP, ChIP etc.
regulated up-regulated
function description In the present study, the high expression of lncRNA H19 was identified as a powerful factor associated with paclitaxel (PTX) resistance in ERa-positive breast cancer cells, but not in ERa-negative breast cancer cells. LncRNA H19 attenuated cell apoptosis in response to PTX treatment by inhibiting transcription of pro-apoptotic genes BIK and NOXA. H19 was further confirmed to suppress the promoter activity of BIK by recruiting EZH2 and by trimethylating the histone H3 at lysine 27.
pubmed id 27845892
year 2016
title LncRNA H19 confers chemoresistance in ERa-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.
drug V
circulating X
survival V

CopyRight © University of Miami, USA; Harbin Medical University, China